Literature DB >> 12508359

Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.

Jun Qian1, Jochen Truebenbach, Florian Graepler, Philippe Pereira, Peter Huppert, Thomas Eul, Gundula Wiemann, Claus Claussen.   

Abstract

AIM: To introduce an animal model of hepatocellular carcinoma (HCC) in ACI-rats, and to evaluate the therapeutic effects of Poly-lactide-co-glycolide (Plcg) -microspheres in the transarterial chemoembolization (TACE) in this model, as well the value of this model in the experiments of interventional therapy.
METHODS: Subcapsular implantation of a solid Morris Hepatoma 3 924A (1 mm(3)) in the livers was carried out in 11 male ACI-rats. The tumor volume (V1) was measured by magnetic resonance imaging (MRI) (13 days after implantation). After laparotomy and retrograde placement of catheter into the gastroduodenal artery (14 days after implantation), the following protocols of interventional treatment were performed: (A) mitomycin C+Poly-lactide-co-glycolide (Plcg)-microspheres (n=4); (B) 0.9 % NaCl (control group, n=7). 13 days after these therapies the change of the tumor volume (V2) was determined by MRI again.
RESULTS: The success rate of tumor implantation reached to 100 %. The mean tumor volume before TACE (V1) were 0.082 cm(3) in group A and 0.096 cm(3) in group B respectively. The mean tumor volume after TACE (V2) were 0.230 cm(3) in group A and 1.347 cm(3) in group B respectively. The mean V2/V1 were 2.860 in group A and 27.120 in group B respectively. Compared to the control group (group B), groups A showed a significant reduction of tumor growth (P=0.004) in the period of observation.
CONCLUSION: The growth of liver tumor could be obviously prevented by utilizing Plcg-mitomycin-microspheres in TACE in animal model. This rat model of HCC is suitable for the experimental studies of interventional therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12508359      PMCID: PMC4728258          DOI: 10.3748/wjg.v9.i1.94

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

Review 1.  Treatment of hepatocellular carcinoma by interventional methods.

Authors:  T Livraghi
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

2.  [Experimental research about effectiveness of transarterial chemoembolization (TACE) in an animal model of hepatocellular carcinoma].

Authors:  J Qian; G Feng; L Trübenbach; P L Pereira; P E Huppert; C D Claussen
Journal:  J Tongji Med Univ       Date:  2001

3.  Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.

Authors:  K Kamada; T Nakanishi; M Kitamoto; H Aikata; Y Kawakami; K Ito; T Asahara; G Kajiyama
Journal:  J Vasc Interv Radiol       Date:  2001-07       Impact factor: 3.464

4.  Transcatheter arterial chemoembolization of hepatocellular carcinoma.

Authors:  J W Chung
Journal:  Hepatogastroenterology       Date:  1998-08

5.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  L Lladó; J Virgili; J Figueras; C Valls; J Dominguez; A Rafecas; J Torras; J Fabregat; J Guardiola; E Jaurrieta
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

Review 6.  Intra-arterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  J C Trinchet; N Ganne-Carrie; M Beaugrand
Journal:  Hepatogastroenterology       Date:  1998-08

7.  Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients.

Authors:  Brian I Carr
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

8.  Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rats.

Authors:  A Hagiwara; C Sakakura; H Tsujimoto; T Imanishi; M Ohgaki; J Yamasaki; K Sawai; T Takahashi; T Fujita; A Yamamoto; S Muranishi; Y Ikada
Journal:  Anticancer Drugs       Date:  1997-02       Impact factor: 2.248

Review 9.  Surgery and ablative therapy for hepatocellular carcinoma.

Authors:  Charles Cha; Ronald P DeMatteo; Leslie H Blumgart
Journal:  J Clin Gastroenterol       Date:  2002 Nov-Dec       Impact factor: 3.062

Review 10.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

View more
  19 in total

1.  Combined transarterial chemoembolization and arterial administration of Bletilla striata in treatment of liver tumor in rats.

Authors:  Jun Qian; Daryusch Vossoughi; Dirk Woitaschek; Elsie Oppermann; Wolf O Bechstein; Wei-Yong Li; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

2.  [Experimental study in the effects of transarterial immuno-chemoembolization in hepatocellular carcinoma].

Authors:  Jun Qian; Lan Ni; Daryusch Vossoughi; Elsie Oppermann; Adel Maataoui; Thomas Josef Vogl
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.

Authors:  Jun Qian; Elsie Oppermann; Andreas Tran; Ulli Imlau; Kun Qian; Thomas Josef Vogl
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

4.  Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.

Authors:  Jeane Chen; Sarah B White; Kathleen R Harris; Weiguo Li; Jonathan W T Yap; Dong-Hyun Kim; Robert J Lewandowski; Lonnie D Shea; Andrew C Larson
Journal:  Biomaterials       Date:  2015-05-15       Impact factor: 12.479

5.  Preparation of human hepatocellular carcinoma-targeted liposome microbubbles and their immunological properties.

Authors:  Ai-Na Bian; Yun-Hua Gao; Kai-Bin Tan; Ping Liu; Gong-Jun Zeng; Xin Zhang; Zheng Liu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

Review 6.  Combined interventional therapies of hepatocellular carcinoma.

Authors:  Jun Qian; Gan-Sheng Feng; Thomas Vogl
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  Study on the effect of chemoembolization combined with microwave ablation for the treatment of hepatocellular carcinoma in rats.

Authors:  Thomas Josef Vogl; Jun Qian; Andreas Tran; Elsie Oppermann; Nagy N Naguib; Huedayi Korkusuz; Nour Eldin A Nour Eldin; Wolf Otto Bechstein
Journal:  Diagn Interv Radiol       Date:  2017 Mar-Apr       Impact factor: 2.630

8.  Changes of tumor microcirculation after transcatheter arterial chemoembolization: first pass perfusion MR imaging and Chinese ink casting in a rabbit model.

Authors:  Jun-Gong Zhao; Gan-Sheng Feng; Xiang-Quan Kong; Xin Li; Ming-Hua Li; Ying-Sheng Cheng
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 9.  Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?

Authors:  Julius Chapiro; Rafael Duran; Jean-François Geschwind
Journal:  Radiol Med       Date:  2014-06-04       Impact factor: 3.469

10.  Assessment of hepatocellular carcinoma vascularity before and after transcatheter arterial chemoembolization by using first pass perfusion weighted MR imaging.

Authors:  Jun-Gong Zhao; Gan-Sheng Feng; Xiang-Quan Kong; Xin Li; Ming-Hua Li; Ying-Sheng Cheng
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.